Literature DB >> 6203975

Augmentation of human natural cell-mediated cytotoxicity by recombinant human interleukin 2.

L P Svedersky, H M Shepard, S A Spencer, M R Shalaby, M A Palladino.   

Abstract

Human peripheral blood mononuclear cells (PBMC) demonstrated increased natural cell-mediated cytotoxicity (NCMC) activity after only 5 min of exposure to purified recombinant human IL 2 or interferon (IFN)-gamma. The mechanism of NCMC augmentation by treatment with IL 2 is not entirely dependent on IFN-gamma production because: a) IL 2 was found to augment NCMC activity at levels which did not induce detectable IFN-gamma; b) IL 2 required only 5 min of exposure to PBMC to augment NCMC activity, whereas 3 hr of contact were required to demonstrate detectable IFN-gamma levels; c) the levels of NCMC enhancement by treatment with IL 2 exceeded the amount of NCMC enhancement that could be due to IFN alone; d) anti-recombinant IFN-gamma, which totally eliminated the augmentation of NCMC enhancement by IFN-gamma, only partially reduced the augmentation of NCMC activity by IL 2; and e) combination treatment of PBMC with IL 2 and IFN-gamma resulted in a synergistic enhancement of NCMC. The results strongly support the conclusion that augmentation of NCMC by IL 2 and IFN-gamma involve overlapping mechanisms.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6203975

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

Review 1.  Exercise and natural killer cells. What is the relationship?

Authors:  L T Mackinnon
Journal:  Sports Med       Date:  1989-03       Impact factor: 11.136

2.  Interleukin 2 enhances natural killing of varicella-zoster virus-infected targets.

Authors:  M Ito; S Bandyopadhyay; M Matsumoto-Kobayashi; S C Clark; D Miller; S E Starr
Journal:  Clin Exp Immunol       Date:  1986-07       Impact factor: 4.330

3.  Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin.

Authors:  C J Honsik; G Jung; R A Reisfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

4.  Effects of interferons and interleukin 2 on natural killing of cytomegalovirus-infected fibroblasts.

Authors:  S Bandyopadhyay; D S Miller; M Matsumoto-Kobayashi; S C Clark; S E Starr
Journal:  Clin Exp Immunol       Date:  1987-02       Impact factor: 4.330

5.  Immunoregulatory dysfunctions in type I diabetes: natural and antibody-dependent cellular cytotoxic activities.

Authors:  M P Nair; E W Lewis; S A Schwartz
Journal:  J Clin Immunol       Date:  1986-09       Impact factor: 8.317

6.  Selective impairment of alpha-interferon-mediated natural killer augmentation in Sjögren's syndrome: differential effects of alpha-interferon, gamma-interferon, and interleukin 2 on cytolytic activity.

Authors:  A Takeda; N Minato; S Kano
Journal:  Clin Exp Immunol       Date:  1987-11       Impact factor: 4.330

7.  Indirect inhibition of generation of murine lymphokine-activated killer cell activity in splenocyte cultures by interferon-gamma.

Authors:  T Y Chao; H Ohnishi; T M Chu
Journal:  Immunology       Date:  1990-05       Impact factor: 7.397

8.  Limiting dilution analysis (LDA) of cells responding to recombinant interleukin-2 without previous stimulation: evidence that all responding cells are lymphokine-activated potent effectors.

Authors:  H Vie; M Bonneville; P Sondermeyer; J F Moreau; J P Soulillou
Journal:  Immunology       Date:  1986-03       Impact factor: 7.397

9.  Short-term lymphokine stimulation of human peripheral blood mononuclear cells generates cytolytic activity against endothelial cells: involvement of natural killer cells.

Authors:  A M Miltenburg; M E Meijer-Paape; M R Daha; L C Paul
Journal:  Immunology       Date:  1988-09       Impact factor: 7.397

10.  Interferon-gamma (IFN-gamma) and interleukin-2 in the generation of lymphokine-activated killer cell cytotoxicity--IFN-gamma-induced suppressive activity.

Authors:  M Toledano; C Mathiot; J Michon; G Andreu; D Lando; M Brandely; W H Fridman
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.